Navigation Links
Einstein researchers find key gene in childhood cancer
Date:5/5/2011

May 5, 2011 (BRONX, NY) There are no effective treatments for rhabdoid tumors aggressive childhood cancers that usually strike children under three years old and affect the brain or kidneys. The disease is extremely rare fewer than 10 cases are diagnosed each year in the U.S. but is particularly difficult to treat and almost always fatal.

Now scientists at Albert Einstein College of Medicine of Yeshiva University have identified a target for potential therapies for these tumors: a gene called Aurora A that is vital for tumor growth. The research team was led by Ganjam Kalpana, Ph.D., professor of genetics and of microbiology & immunology, the Mark Trauner Faculty Scholar in Neuro-oncology at Einstein. Their findings appear in the April 26 online issue of Cancer Research.

The Aurora A gene is known to be expressed at higher-than-normal levels in many cancers, and its expression is associated with poor prognosis. Scientists have also known that mutations in a tumor suppressor gene called INI1/hSNF5 can lead to rhabdoid tumors. In this study, the Kalpana team found that, in rhabdoid tumors, loss of the tumor suppressor gene INI1/hSNF5 leads to changes in Aurora A's expression that are crucial for tumor growth.

In experiments involving rhabdoid tumors and tumor cell lines, the Einstein scientists showed for the first time that Aurora A is highly expressed in both human and mouse rhabdoid tumors, that the loss of the INI1/hSNF5 tumor suppressor gene from rhabdoid tumor cells leads to the "de-repression" of Aurora A, and that knocking down Aurora A's expression in rhabdoid tumor cells potently inhibits the growth of those cells.

"Our findings indicate that targeting Aurora A could be an effective strategy for halting rhabdoid tumor growth," said Dr. Kalpana. She notes that many Aurora A inhibitors are now being tested against several types of cancers, includingmelanoma and non-Hodgkin's lymphoma, and other researchers have now expressed interest in using Aurora A inhibitors in trials for children with rhabdoid brain tumors.


'/>"/>

Contact: Kim Newman
sciencenews@einstein.yu.edu
718-430-3101
Albert Einstein College of Medicine
Source:Eurekalert

Related biology news :

1. Albert Einstein College of Medicine geneticist wins Sloan Research Fellowship
2. Einstein researcher receives American Cancer Society Medal of Honor
3. Einstein receives $30 million to study protein form and function
4. Einstein designated an NIH Center of Excellence for aging research
5. Einstein receives $4 million to test HPV microbicide
6. Einstein researcher awarded prestigious cancer research grant
7. Einstein-Montefiore research tackles childhood obesity in the Bronx
8. Einstein researchers discover 2 new ways to kill TB
9. Einstein receives high-risk/high-reward cancer research funding
10. Einstein to develop anti-HIV drug delivery system
11. Einstein scientists move closer to a safer anthrax vaccine
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/6/2016)... , Dec. 6, 2016  Zimmer Biomet Holdings, Inc. ... has priced an offering of €500.0 million principal amount of ... principal amount of its 2.425% senior unsecured notes due 2026. ... to occur on December 13, 2016, subject to the satisfaction of ... annual basis. The Company intends ...
(Date:12/6/2016)... -- Securus Technologies, a leading provider of civil ... investigation, corrections and monitoring, and the Prison Entrepreneurship ... year funding commitment by Securus to PEP and ... reentry support to more inmates and their families. ... Prison Entrepreneurship Program (PEP) is an independent 501(c)(3) ...
(Date:12/2/2016)... 2016 The report "Biometric Vehicle ... Technology (Iris Recognition System), Vehicle Type (Passenger Car, ... to 2021", published by MarketsandMarkets, the market is ... and is projected to grow to USD 854.8 ...      (Logo: http://photos.prnewswire.com/prnh/20160303/792302) ...
Breaking Biology News(10 mins):
(Date:12/9/2016)... According to a new market research report "Oligonucleotide Synthesis Market ... (Research, PCR, Gene, DNA, NGS, Diagnostic, RNAI), End user (Academic, Pharmaceutical, ... is expected to reach USD 2.20 Billion by 2021 from USD ... forecast period. Continue Reading ... ...
(Date:12/8/2016)... ... December 08, 2016 , ... From wearable devices ... taking over sports. On Thursday, December 15th a panel of entrepreneurs, innovators and ... playing field at a Smart Talk session. Smart Talk will run from 8:30 ...
(Date:12/8/2016)... BELLINGHAM, Washington, USA, and CARDIFF, UK (PRWEB) , ... ... ... neural circuits with very high precision light to control cells — optogenetics — ... brain. In the current state of the art, spatially patterned light projected via ...
(Date:12/8/2016)... ... 2016 , ... KBioBox llc announced today the launch of ... a sophisticated “3 click” gene dditing off target analysis program and a “3 ... https://www.kbiobox.com/ and powered by the company’s proprietary BioEngine. Scientists, pharmaceutical researchers ...
Breaking Biology Technology: